Real-world evidence on fremanezumab for migraine treatment in Japan: a retrospective analysis

被引：0
|
作者：
Takizawa, T. [1 ]
Ohtani, S. [1 ,2 ]
Watanabe, N. [1 ]
Ihara, K. [1 ]
Takahashi, N. [1 ]
Miyazaki, N. [3 ]
Ishizuchi, K. [1 ]
Takemura, R. [3 ]
Hori, S. [2 ]
Nakahara, J. [1 ]
机构：
[1] Keio Univ, Sch Med, Dept Neurol, Tokyo, Japan
[2] Keio Univ, Fac Pharm, Div Drug Informat, Tokyo, Japan
[3] Keio Univ Hosp, Biostat Unit, Clin & Translat Res Ctr, Tokyo, Japan
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P254
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
    Ohtani, Seiya
    Watanabe, Narumi
    Ihara, Keiko
    Takahashi, Nobuyuki
    Miyazaki, Naoki
    Ishizuchi, Kei
    Takemura, Ryo
    Hori, Satoko
    Nakahara, Jin
    Takizawa, Tsubasa
    BMC NEUROLOGY, 2023, 23 (01)
  • [2] Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
    Seiya Ohtani
    Narumi Watanabe
    Keiko Ihara
    Nobuyuki Takahashi
    Naoki Miyazaki
    Kei Ishizuchi
    Ryo Takemura
    Satoko Hori
    Jin Nakahara
    Tsubasa Takizawa
    BMC Neurology, 23
  • [3] Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
    Takizawa, Tsubasa
    Ohtani, Seiya
    Watanabe, Narumi
    Miyazaki, Naoki
    Ishizuchi, Kei
    Sekiguchi, Koji
    Iba, Chisato
    Shibata, Mamoru
    Takemura, Ryo
    Hori, Satoko
    Nakahara, Jin
    BMC NEUROLOGY, 2022, 22 (01)
  • [4] Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
    Tsubasa Takizawa
    Seiya Ohtani
    Narumi Watanabe
    Naoki Miyazaki
    Kei Ishizuchi
    Koji Sekiguchi
    Chisato Iba
    Mamoru Shibata
    Ryo Takemura
    Satoko Hori
    Jin Nakahara
    BMC Neurology, 22
  • [5] Real-world evidence of galcanezumab for migraine treatment in Japan: A retrospective analysis
    Takizawa, T.
    Ohtani, S.
    Watanabe, N.
    Miyazaki, N.
    Ishizuchi, K.
    Sekiguchi, K.
    Iba, C.
    Shibata, M.
    Takemura, R.
    Hori, S.
    Nakahara, J.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [6] Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
    Suzuki, Shiho
    Suzuki, Keisuke
    Shiina, Tomohiko
    Haruyama, Yasuo
    Hirata, Koichi
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [7] Real-world evidence of monoclonal antibodies for migraine treatment in Argentina: a retrospective analysis
    Vanesa Nagel, Maria
    Portuondo, Gustavo
    Bravo, Yasmin
    Mariela, Grandinetti
    Calvo, Daniela
    Gutierrez, Teresa
    Larripa, Natalia
    Tajan, Emilia
    Crema, Santiago
    Bonamico, Lucas
    Teresa Goicochea, Maria
    CEPHALALGIA, 2023, 43 (1supp) : 254 - 255
  • [8] Real-world effectiveness after initiating fremanezumab treatment of 165 migraine patients in a regional headache center in Japan
    Kikui, Shoji
    Danno, Daisuke
    Miyahara, Junichi
    Sugyama, Hanako
    Ota, Kuniko
    Murakata, Kenji
    Kashiwaya, Yoshihiro
    Takeshima, Takao
    CEPHALALGIA, 2023, 43 (1supp) : 236 - 236
  • [9] Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
    Driessen, Maurice T.
    Cohen, Joshua M.
    Patterson-Lomba, Oscar
    Thompson, Stephen F.
    Seminerio, Michael
    Carr, Karen
    Totev, Todor, I
    Sun, Rochelle
    Yim, Erica
    Mu, Fan
    Ayyagari, Rajeev
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [10] Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
    Maurice T. Driessen
    Joshua M. Cohen
    Oscar Patterson-Lomba
    Stephen F. Thompson
    Michael Seminerio
    Karen Carr
    Todor I. Totev
    Rochelle Sun
    Erica Yim
    Fan Mu
    Rajeev Ayyagari
    The Journal of Headache and Pain, 2022, 23
12345